West Pharmaceutical Services, Inc. (WST)
Healthcare · end-of-day data as of Oct 16, 2026
The average 12-month analyst price target for WST is $391.16, 1.9% above the last close of $384.02 on Oct 16, 2026; targets range from $287.03 to $454.28. Rating consensus: Buy.
Snapshot
- P/E49.1x
- P/E vs sector+74.4%
- P/E vs own+23.8%
- Target upside+1.9%
- ConsensusBuy
- Market cap$27.03B
- FCF yield+1.6%
- Insiders-$3.52M
- Earnings in13d
- News0.00
Why it moved
West Pharmaceutical Services, Inc. (WST) rose 0.3% on Oct 16, 2026.
The market (SPY) fell 1.1%; Healthcare stocks fell 0.7%. Most of the move came from the market as a whole.
0 stories on the day (30-day average 0.3).
Market = SPY. Sector = equal-weight average of the tracked companies in the same sector, net of the market.
Price and events
Last close $384.02 · +44.2% over 1y · E earnings · D dividend · S split · A analyst rating change
Technicals
- Trendsideways
- Sector▲ +16.0%
- MAs20▲ 50▲ 100▲ 200▲
- Above MAs4 of 4 above
- MA20×50—
- RSI66
- Support-6.6%
- Resistance—
- Off 52w high0.0%
- Off ATH-17.5%
- 52w range$384.02
- Bollingerabove upper
- MACD0.65
- ATR+2.3%
- Volume1.0x
Analyst price targets
8 firms with a target in the last 12 months · last close $384.02 · as of Oct 16, 2026
Strong buy 4 · Buy 12 · Hold 1 · Sell 0 · Strong sell 0
Revenue and free cash flow
Q2 FY2026: Revenue +13.8% year over year, free cash flow 9.3% of revenue, operating margin 20.5%.
| Q2 FY2026 | Jun 30, 2026 | $872M | 2.15 | $80.8M | 37.7% | 20.5% | 17.7% |
| Q1 FY2026 | Mar 31, 2026 | $845M | 1.92 | $47.2M | 35.1% | 21.0% | 16.4% |
| Q4 FY2025 | Dec 31, 2025 | $805M | 1.82 | $175M | 37.8% | 19.5% | 16.4% |
| Q3 FY2025 | Sep 30, 2025 | $804M | 1.93 | $134M | 36.5% | 21.6% | 17.4% |
| Q2 FY2025 | Jun 30, 2025 | $766M | 1.82 | $102M | 35.7% | 20.6% | 17.2% |
| Q1 FY2025 | Mar 31, 2025 | $698M | 1.23 | $58.1M | 33.3% | 18.4% | 12.9% |
| Q4 FY2024 | Dec 31, 2024 | $749M | 1.78 | $85.2M | 36.7% | 22.8% | 17.4% |
| Q3 FY2024 | Sep 30, 2024 | $747M | 1.85 | $98.8M | 35.5% | 22.5% | 18.2% |
Peers
| 20D | ||||||||
|---|---|---|---|---|---|---|---|---|
| 1 |  | $426.70 | -0.3% | -28.0% | +12.1% | 48.5 | $151B | |
| 2 |  | $191.75 | -1.0% | -1.0% | -6.2% | 57.8 | $52.23B | |
| 3 |  | $238.97 | -1.3% | -12.7% | +3.7% | 23.0 | $33.61B | |
| 4 | | $384.02 | +0.3% | 0.0% | +1.9% | 49.1 | $27.03B | |
| 5 |  | $235.00 | -1.7% | -4.7% | -0.5% | 24.9 | $25.94B | |
| 6 |  | $85.81 | -2.3% | -7.2% | +3.6% | 10.5 | $14.61B | |
| 7 |  | $25.28 | -1.9% | -10.8% | -14.8% | — | $13.07B | |
| 8 |  | $57.94 | +0.9% | -31.3% | +0.9% | 19.8 | $11.02B |
Data as of Oct 16, 2026 close.
Latest news
Sentiment classified by AI from the headline (green positive, red negative). Links open the publisher.